MORF-057 is under clinical development by Morphic Therapeutic and currently in Phase II for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase II drugs for Crohn’s Disease (Regional Enteritis) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MORF-057’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MORF-057 overview
MORF-057 is under development for the treatment of autoimmune disorders including ulcerative colitis, Crohn's disease and eosinophilic esophagitis. It is administered orally. It is developed based on Morphic integrin technology (MInT). The drug candidate acts by targeting integrin alpha 4 and beta 7.
Morphic Therapeutic overview
Morphic Therapeutic Inc is a biotechnology firm. The company develops oral integrin medicines for the treatment of chronic diseases. The company also develops medicines for the treatment of autoimmune diseases, cardiovascular diseases, metabolic diseases, fibrosis and cancer. The company develops and manufactures the products through distributors, and third-party partners in the market. The product of oral integrin has developed six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn’s disease, plaque psoriasis, and acute coronary syndrome The company focuses completely on autoimmune diseases, fibrosis and cancer. Morphic Therapeutic is headquartered in the United States.
For a complete picture of MORF-057’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.